InfuSystem Holdings

Recent signals

• May 11, 2026: SEC 8-K (5.02): Following the 2026 Annual Meeting of Stockholders held on May 11, 2026, InfuSystem Holdings, Inc. appointed Beverly Huss as the new Chairman of the Board of Directors. This election came as a result of the reconstitution of the Board. There are no arrangements or understandings with any other persons regarding her appointment, and Ms. Huss does not have any family relationships with other directors or executive officers of the company, nor does she have any material interest in any transactions that require disclosure. The change in leadership may impact the company’s governance structure and strategic direction moving forward.
• Feb 27, 2026: SEC 8-K (7.01): InfuSystem Holdings, Inc. furnished an Investor Presentation dated February 27, 2026, as part of its Regulation FD Disclosure under Item 7.01 of Form 8-K. This presentation contains important information intended for investors and stakeholders regarding the company’s current operations and strategic direction. While specific financial amounts are not detailed in the filing, the timing of the presentation suggests it may include recent achievements or updates that could impact investor perception. The event date of the presentation aligns exactly with the filing date, ensuring its relevance.
• Feb 24, 2026: SEC 8-K (2.02): On February 24, 2026, InfuSystem Holdings, Inc. reported its financial results for the fourth quarter and fiscal year 2025. The press release, attached as Exhibit 99.1 to the Form 8-K, details the company's performance metrics, revenue figures, and net income for the reported period. This financial disclosure is pivotal for investors assessing the company's condition and future prospects following a full fiscal year. Notably, this announcement comes at a time when stakeholders are closely monitoring the company's financial health and strategic directions.
• Feb 17, 2026: SEC 8-K (7.01): On February 17, 2026, InfuSystem Holdings, Inc. announced its plans to disclose preliminary financial results for the fourth quarter and fiscal year 2025 on February 24, 2026, before the market opens. Additionally, the Company is set to hold a conference call for investors on the same date at 9:00 a.m. Eastern Time. This announcement is significant as it sets the timeline for when investors can expect key financial data related to the Company’s performance. The press release accompanying this information is furnished under Item 7.01 of the Form 8-K.
• Feb 17, 2026: SEC 8-K (7.01): On February 17, 2026, InfuSystem Holdings, Inc. announced via a press release that it will disclose its preliminary financial results for the fourth quarter and fiscal year 2025 on February 24, 2026. The press release also stated that a conference call for investors will be held on the same day at 9:00 a.m. Eastern Time. This announcement is essential for investors as it provides insights into the company's financial performance and offers an opportunity for direct engagement during the upcoming conference call.
• Nov 18, 2024: Launched InfuSystem Holdings, Inc. welcomes Ronald Hundzinski to its Board of Directors to enhance its oversight and business strategy.
• Aug 06, 2024: InfuSystem Announces Distribution Agreement with Smith+Nephew for Negative Pressure Wound Therapy System